Zoledronic Acid Attenuates Early Bone Loss at Forearm in Patients with Acute Spinal Cord Injury

Overview

Journal Indian J Orthop

Publisher Springer Nature

Specialty Orthopedics

Date 2020 Sep 21

PMID 32952920

Citations 3

Authors

Sunil Goenka

Satyaranjan Sethi

Affiliations

Soon will be listed here.

Abstract

Study Design: Randomized controlled trial.

Objectives: To study the magnitude of bone loss at forearm in persons with acute spinal cord injury (SCI) & the effect of early administration of Zoledronic acid on its' prevention.

Settings: Sawai Man Singh Medical College, Jaipur, India.

Methods: Sixty patients with acute SCI were randomized either to receive standard medical and nursing care or Zoledronic acid infusion in combination with standard medical and nursing care. Areal bone mineral density (aBMD) was measured at the forearm (radius + ulna) once patients were medically stable using Dual Energy X-Ray Absorptiometry (DXA) at baseline and at 3, 6 and 12 months.

Results: Significant differences in aBMD was found between the control & Zoledronic acid group at 1/3 forearm (- 0.064; 95% CI - 0.092 to - 0.036, = 0.001), mid forearm (- 0.059; 95% CI - 0.084 to - 0.034, = 0.001), UD forearm (- 0.048; 95% CI - 0.097 to 0.001, = 0.016) and total forearm (- 0.048; 95% CI - 0.088 to - 0.008, = 0.021) at 1 year in the paraplegic patients with SCI. Similar significant difference was also observed at 1/3 forearm (- 0.046; 95% CI - 0.073 to - 0.019, = 0.002), mid forearm (- 0.063; 95% CI - 0.088 to - 0.037, < 0.0001), UD forearm (- 0.084; 95% CI - 0.101 to - 0.067, < 0.0001) and total forearm (- 0.115; 95% CI - 0.132 to - 0.097, < 0.0001) respectively at 1 year in the quadriplegic patients with SCI. Significant differences in aBMD between the groups at 6 months post infusion was also observed at these sites in quadriplegic patients. [1/3 forearm - 0.022; 95% CI - 0.039 to - 0.005; = 0.015, Mid forearm - 0.023; 95% CI - 0.042 to - 0.004; = 0.019, UD forearm - 0.041; 95% CI - 0.055 to - 0.027; < 0.0001 and Total forearm - 0.049; 95%CI - 0.062 to - 0.036; < 0.0001]. Bone loss was reduced in the Zoledronic acid treated group compared to the standard treatment group in both paraplegic and quadriplegic patients.

Conclusion: Single dose of 5mg intravenous Zoledronic acid is an effective treatment in preventing bone loss at the forearm for 12 months following acute spinal cord injury.

Citing Articles

Polydatin administration attenuates the severe sublesional bone loss in mice with chronic spinal cord injury.

Zhan J, Luo D, Zhao B, Chen S, Luan J, Luo J Aging (Albany NY). 2022; 14(21):8856-8875.

PMID: 36378815 PMC: 9699758. DOI: 10.18632/aging.204382.

Effect of External Mechanical Stimuli on Human Bone: a narrative review.

Mancuso M, Wilzman A, Murdock K, Troy K Prog Biomed Eng (Bristol). 2022; 4(1).

PMID: 36310606 PMC: 9616042. DOI: 10.1088/2516-1091/ac41bc.

Bone Mineral Density Post a Spinal Cord Injury: A Review of the Current Literature Guidelines.

Antoniou G, Benetos I, Vlamis J, Pneumaticos S Cureus. 2022; 14(3):e23434.

PMID: 35494917 PMC: 9038209. DOI: 10.7759/cureus.23434.

References

Gilchrist N, Frampton C, Acland R, Nicholls M, March R, Maguire P . Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2007; 92(4):1385-90. DOI: 10.1210/jc.2006-2013. View

Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V . Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002; 23(4):508-16. DOI: 10.1210/er.2001-2002. View

Frey-Rindova P, de Bruin E, Stussi E, Dambacher M, Dietz V . Bone mineral density in upper and lower extremities during 12 months after spinal cord injury measured by peripheral quantitative computed tomography. Spinal Cord. 2000; 38(1):26-32. DOI: 10.1038/sj.sc.3100905. View

Modlesky C, Majumdar S, Narasimhan A, Dudley G . Trabecular bone microarchitecture is deteriorated in men with spinal cord injury. J Bone Miner Res. 2004; 19(1):48-55. DOI: 10.1359/JBMR.0301208. View

Widler L, Jaeggi K, Glatt M, Muller K, Bachmann R, Bisping M . Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem. 2002; 45(17):3721-38. DOI: 10.1021/jm020819i. View

Schnitzer T, Kim K, Marks J, Yeasted R, Simonian N, Chen D . Zoledronic Acid Treatment After Acute Spinal Cord Injury: Results of a Randomized, Placebo-Controlled Pilot Trial. PM R. 2016; 8(9):833-43. DOI: 10.1016/j.pmrj.2016.01.012. View

Bubbear J, Gall A, Middleton F, Ferguson-Pell M, Swaminathan R, Keen R . Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury. Osteoporos Int. 2010; 22(1):271-9. DOI: 10.1007/s00198-010-1221-6. View

Jiang S, Dai L, Jiang L . Osteoporosis after spinal cord injury. Osteoporos Int. 2005; 17(2):180-92. DOI: 10.1007/s00198-005-2028-8. View

Jiang S, Jiang L, Dai L . Mechanisms of osteoporosis in spinal cord injury. Clin Endocrinol (Oxf). 2006; 65(5):555-65. DOI: 10.1111/j.1365-2265.2006.02683.x. View

10.

Shapiro J, Smith B, Beck T, Ballard P, Dapthary M, BrintzenhofeSzoc K . Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury. Calcif Tissue Int. 2007; 80(5):316-22. DOI: 10.1007/s00223-007-9012-6. View

11.

Slade J, Bickel C, Modlesky C, Majumdar S, Dudley G . Trabecular bone is more deteriorated in spinal cord injured versus estrogen-free postmenopausal women. Osteoporos Int. 2004; 16(3):263-72. DOI: 10.1007/s00198-004-1665-7. View

12.

Green J, Muller K, Jaeggi K . Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994; 9(5):745-51. DOI: 10.1002/jbmr.5650090521. View

13.

Kiratli B, Smith A, Nauenberg T, Kallfelz C, Perkash I . Bone mineral and geometric changes through the femur with immobilization due to spinal cord injury. J Rehabil Res Dev. 2000; 37(2):225-33. View